DALLAS, June 17, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring biopharmaceutical stock Allos Therapeutics Inc. (Nasdaq:ALTH). The report includes the most ...
Martin Shkreli, MSMB Capital has succeeded in derailing the acquisition of Allos Therapeutics Inc. (ALTH) by AMAG Pharmaceuticals Inc. (AMAG). According to Bloomberg, AMAG announced today that “it ...
WESTMINSTER, Colo.--(BUSINESS WIRE)--Oct. 13, 2009-- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the closing of its previously announced underwritten public offering of 14,000,000 shares ...
Allos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma WESTMINSTER, Colo.--(BUSINESS WIRE)--Aug ...
Get unlimited access to ad-free articles and exclusive content. What: Allos Therapeutics, Inc. (ALTH) will visit the NASDAQ MarketSite in New York City's Times Square. In honor of the occasion and in ...
Spectrum PharmaceuticalsShiv Kapoor, 702-835-6300Vice President, Strategic Planning & Investor RelationsorAllos TherapeuticsMonique Greer, 720-540-5268Vice President, Corporate Communications & ...
Henderson-based Spectrum Pharmaceuticals Inc. said Thursday it would acquire Allos Therapeutics Inc. in a deal valued as much as $206 million. Terms of the acquisition call for Spectrum to pay $1.82 a ...
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today that the Agreement and Plan of Merger and Reorganization ("the Merger Agreement") entered into by and among ...
We have recently downgraded Allos Therapeutics Inc. ( ALTH) to Neutral from Outperform with a target price of $1.50. The failure of Allos' deal with AMAG Pharma ( AMAG) in October 2011 has reverted ...
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced the Company will hold a webcast conference call on Wednesday, September 2, 2009 to discuss the outcome of ...
Mundipharma agreed to pay $310.5 million in milestones, gaining rights outside the U.S. and Canada. Allos Therapeutics could see up to $360.5 million under a collaboration with Mundipharma to ...
Allos Therapeutics, Inc. (ALTH) will visit the NASDAQ MarketSite in New York City's Times Square. In honor of the occasion and in honor of patients with blood cancers and their families, Dr. Charles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results